search
Back to results

Research on Diagnosis and Prognosis of Myocardial Ischemia Level Using Magnetocardiography

Primary Purpose

Stable Ischemic Heart Disease; Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Magnetocardiography
Sponsored by
Xiangya Hospital of Central South University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Stable Ischemic Heart Disease; Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥18 years old; Those who are suspected of coronary heart disease and scheduled to undergo coronary angiography; Sign the informed consent. Exclusion Criteria: Complex arrhythmia, including frequent premature atrial beats, premature ventricular beats, atrial fibrillation, atrial flutter, and complete bundle branch block; Severe hypertension (> 180/110 mmHg); Congenital heart diseases, valvular heart diseases, or implantation of pacemakers or drug pumps. Severe thoracic or pulmonary diseases, thoracic malformation, or history of thoracic surgery; Pregnant or breastfeeding women; Claustrophobia, or those who can't lie still for 2 minutes in a confined space; Allergy to contrast agent; Renal impairment: serum creatinine > 2,0 mg/dl (176.8 μmol/L) or those who are receiving hemodialysis; Other diseases, including malignant tumors, organ transplantation, and candidates for organ transplantation; History of alcohol or drug abuse (cocaine, heroin, etc.); Participating in clinical studies of other drugs or devices without reaching the time limit for the primary endpoint; Those who aren't suitable for inclusion due to other reason.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Coronary stenosis

    Control

    Arm Description

    Outcomes

    Primary Outcome Measures

    Sensitivity of diagnosis of myocardial infarction level
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. And calculate the sensitivity to evaluate the diagnosis of myocardial infarction level validity.
    Specificity of diagnosis of myocardial infarction level
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. And calculate the specificity to evaluate the diagnosis of myocardial infarction level validity.
    Consistency of diagnosis of myocardial infarction level
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. Calculate the consistency to evaluate the diagnosis of myocardial infarction level reliability.
    Kappa statistics of diagnosis of myocardial infarction level
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. Calculate the Kappa statistics to evaluate the diagnosis of myocardial infarction level reliability.

    Secondary Outcome Measures

    Incidence of major adverse cardiovascular events
    Participants are followed up by telephone at 1, 3, 6, 12, 24, 36, 48, and 60 months after recruitment and ask whether major adverse cardiac events (MACE) have happened. MACE will be defined as acute myocardial infarction, coronary revascularization, stroke, and all-cause death. According to incidence of MACE, draw the Kaplan-Meier curve and establish Cox regression model.Establish a risk-predicted model of MCG for detecting myocardial infarction

    Full Information

    First Posted
    December 25, 2022
    Last Updated
    January 29, 2023
    Sponsor
    Xiangya Hospital of Central South University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05718206
    Brief Title
    Research on Diagnosis and Prognosis of Myocardial Ischemia Level Using Magnetocardiography
    Official Title
    Research on Diagnosis and Prognosis of Myocardial Ischemia Level in Xiangya Hospital Using Magnetocardiography -- Miracle MCG
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    February 15, 2023 (Anticipated)
    Primary Completion Date
    August 14, 2023 (Anticipated)
    Study Completion Date
    August 14, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Xiangya Hospital of Central South University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Magnetocardiography (MCG) is a non-invasive and accurate method of detecting myocardial ischemia. However, the previous MCG is limited in clinical practice due to its high working conditions and limited sensitivity. The next-generation MCG based on optical pumped magnetometer (OPM) has the advantages of high sensitivity, high reliability, high usability and low cost, which makes it suitable for most medical scenarios. Thus, this prospective single-center study aimed to use OPM MCG to explore its diagnostic efficacy and predictive value for myocardial ischemia. Participants who will receive coronary angiography examinations will be enrolled in this study. Participants enrolled in the study will also have a 1, 3, 6, 12, 24, 36, and 48-month follow-up for analysis of adverse cardiac events.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Stable Ischemic Heart Disease; Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    146 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Coronary stenosis
    Arm Type
    Experimental
    Arm Title
    Control
    Arm Type
    Other
    Intervention Type
    Device
    Intervention Name(s)
    Magnetocardiography
    Intervention Description
    Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
    Primary Outcome Measure Information:
    Title
    Sensitivity of diagnosis of myocardial infarction level
    Description
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. And calculate the sensitivity to evaluate the diagnosis of myocardial infarction level validity.
    Time Frame
    up to 6 months
    Title
    Specificity of diagnosis of myocardial infarction level
    Description
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. And calculate the specificity to evaluate the diagnosis of myocardial infarction level validity.
    Time Frame
    up to 6 months
    Title
    Consistency of diagnosis of myocardial infarction level
    Description
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. Calculate the consistency to evaluate the diagnosis of myocardial infarction level reliability.
    Time Frame
    up to 6 months
    Title
    Kappa statistics of diagnosis of myocardial infarction level
    Description
    The myocardial ischemic level is measured by MCG and coronary angiography examination. The result of the coronary angiography examination is independently judged by three experienced clinicians. Calculate the Kappa statistics to evaluate the diagnosis of myocardial infarction level reliability.
    Time Frame
    up to 6 months
    Secondary Outcome Measure Information:
    Title
    Incidence of major adverse cardiovascular events
    Description
    Participants are followed up by telephone at 1, 3, 6, 12, 24, 36, 48, and 60 months after recruitment and ask whether major adverse cardiac events (MACE) have happened. MACE will be defined as acute myocardial infarction, coronary revascularization, stroke, and all-cause death. According to incidence of MACE, draw the Kaplan-Meier curve and establish Cox regression model.Establish a risk-predicted model of MCG for detecting myocardial infarction
    Time Frame
    through study completion, an avarage of 2 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age ≥18 years old; Those who are suspected of coronary heart disease and scheduled to undergo coronary angiography; Sign the informed consent. Exclusion Criteria: Complex arrhythmia, including frequent premature atrial beats, premature ventricular beats, atrial fibrillation, atrial flutter, and complete bundle branch block; Severe hypertension (> 180/110 mmHg); Congenital heart diseases, valvular heart diseases, or implantation of pacemakers or drug pumps. Severe thoracic or pulmonary diseases, thoracic malformation, or history of thoracic surgery; Pregnant or breastfeeding women; Claustrophobia, or those who can't lie still for 2 minutes in a confined space; Allergy to contrast agent; Renal impairment: serum creatinine > 2,0 mg/dl (176.8 μmol/L) or those who are receiving hemodialysis; Other diseases, including malignant tumors, organ transplantation, and candidates for organ transplantation; History of alcohol or drug abuse (cocaine, heroin, etc.); Participating in clinical studies of other drugs or devices without reaching the time limit for the primary endpoint; Those who aren't suitable for inclusion due to other reason.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jie Liu
    Phone
    86-18932462423
    Email
    208111002@csu.edu.cn

    12. IPD Sharing Statement

    Learn more about this trial

    Research on Diagnosis and Prognosis of Myocardial Ischemia Level Using Magnetocardiography

    We'll reach out to this number within 24 hrs